Last reviewed · How we verify
Phoslo (CALCIUM ACETATE)
Phoslo works by increasing calcium levels in the blood to treat conditions related to low calcium.
Phoslo (Calcium Acetate) is a small molecule calcium acetate medication originally developed by B Braun and currently owned by Fresenius Medical Care. It is used to treat various electrolyte disorders, including hyperkalemia, hypermagnesemia, and hypocalcemia, as well as renal osteodystrophy with hyperphosphatemia. Phoslo is an off-patent medication with multiple generic manufacturers. Key safety considerations include the potential for hypercalcemia and the need for careful monitoring of calcium levels. Phoslo was FDA-approved in 1982.
At a glance
| Generic name | CALCIUM ACETATE |
|---|---|
| Sponsor | Fresenius Medcl Care |
| Drug class | calcium acetate |
| Modality | Small molecule |
| Therapeutic area | Hematology |
| Phase | FDA-approved |
| First approval | 1982 |
Mechanism of action
Calcium acetate, when taken with meals, combines with dietary phosphate to form an insoluble calcium phosphate complex, which is excreted in the feces, resulting in decreased serum phosphorus concentration.
Approved indications
- Cardiac arrest
- Disorder of electrolytes
- Hyperkalemia
- Hypermagnesemia
- Hypocalcemia
- Hypocalcemic tetany
- Renal Osteodystrophy with Hyperphosphatemia
Common side effects
- Phlebitis
- Thrombosis
- Erythema
- Fever
- Nausea
- Generalized flushing
- Warm sensation
Drug interactions
- ciprofloxacin
- gatifloxacin
- levofloxacin
- moxifloxacin
Key clinical trials
- Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia (PHASE2)
- A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia (PHASE3)
- CB-839 HCl in Combination With Carfilzomib and Dexamethasone in Treating Patients With Recurrent or Refractory Multiple Myeloma (PHASE1)
- Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) With the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple Myeloma (PHASE2)
- Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carfilzomib, Pomalidomide, and Dexamethasone) for Patients With Multiple Myeloma Who Have Relapsed Shortly After Treatment (PHASE1,PHASE2)
- Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia (PHASE2)
- Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse (PHASE2)
- Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults (PHASE3)
Patents
| Patent | Expiry | Type |
|---|---|---|
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
| FDA Orange Book | Patents + exclusivity |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Phoslo CI brief — competitive landscape report
- Phoslo updates RSS · CI watch RSS
- Fresenius Medcl Care portfolio CI